非鳞NSCLC中评估PD-L1表达需单次活检至少100个肿瘤细胞以预测纳武利尤单抗疗效
该研究纳入80例接受纳武利尤单抗治疗的非鳞非小细胞肺癌患者,共222份活检样本,比较含最多肿瘤细胞(Max-TC)与含最少肿瘤细胞(Min-TC)样本及全部样本的PD-L1评分。结果显示Max-TC与Min-TC间PD-L1<1%与≥1%不匹配见于6例(8%),匹配所需最佳肿瘤细胞数为100;Min-TC中肿瘤细胞≥100且PD-L1≥1%者PFS和OS显著更长,而<100个肿瘤细胞时无差异。结论:单次活检至少含100个肿瘤细胞方可用于评估PD-L1以预测纳武利尤单抗疗效。
要点
- 单次活检评估PD-L1预测纳武利尤单抗疗效需至少100个肿瘤细胞。
- 肿瘤细胞<100个时PD-L1≥1%与<1%者PFS和OS无显著差异。
- Max-TC与Min-TC间PD-L1<1%与≥1%不匹配见于6例(8%)。
核心结论
- 单次活检样本需含至少100个肿瘤细胞方可评估PD-L1表达以预测非鳞NSCLC患者对纳武利尤单抗的应答。
研究设计与样本
- 回顾性收集80例接受纳武利尤单抗治疗的非鳞NSCLC患者的222份活检样本。
- 比较每例患者含最多肿瘤细胞样本(Max-TC)、含最少肿瘤细胞样本(Min-TC)及全部样本的肿瘤细胞数与PD-L1评分。
- 评估样本数和肿瘤细胞数对基于PD-L1评分预测纳武利尤单抗应答的影响。
主要发现
- Max-TC与全部样本间PD-L1<1%与≥1%不匹配见于1例(1%),Max-TC与Min-TC间不匹配见于6例(8%)。
- Max-TC与Min-TC间匹配PD-L1<1%与≥1%的最佳肿瘤细胞数为100(敏感度=0.676,1-特异度=0.333)。
- Min-TC含至少100个肿瘤细胞时,PD-L1≥1%者较<1%者PFS更长(中位7.6 vs 1.8个月,p<0.01),OS更长(中位未达到 vs 9.9个月,p=0.04)。
- Min-TC含少于100个肿瘤细胞时,PD-L1≥1%与<1%者PFS(中位3.9 vs 2.3个月,p=0.37)和OS(中位9.7 vs 7.6个月,p=0.60)均无差异。
关键数值与推荐
- 单次活检样本含至少100个肿瘤细胞是评估PD-L1表达以预测纳武利尤单抗应答的最低要求。
临床怎么用
- 临床送检活检样本评估PD-L1以指导纳武利尤单抗治疗时,应确保单次样本含至少100个肿瘤细胞。
- 肿瘤细胞不足100个的样本PD-L1结果可能无法可靠预测纳武利尤单抗的PFS和OS获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Programmed death ligand 1 (PD-L1) expression is a predictive biomarker for patient response to nivolumab in nonsquamous NSCLC. However, the number of biopsy samples and tumor cells (TCs) required to assess PD-L1 expression remains unclear. METHODS: A total of 222 biopsy samples from 80 patients with nonsquamous NSCLC treated with nivolumab were collected. Number of TCs and PD-L1 score were compared among the sample containing the largest number of TCs (Max-TC), the sample containing the smallest number of TCs (Min-TC), and the total samples from each patient. The impact of the number of samples and TCs on the prediction of patient response to nivolumab with use of PD-L1 scores was evaluated. RESULTS: There was a mismatch in PD-L1 scores less than 1% and those of at least 1% between Max-TC and the total samples in one patient (1%) and between Max-TC and Min-TC in six patients (8%). The optimal number of TCs to match PD-L1 expression less than 1% versus at least 1% between Max-TC and Min-TC was 100 (sensitivity = 0.676 and 1 - specificity = 0.333). PD-L1 expression of at least 1% in Min-TCs containing at least 100 TCs was associated with longer progression-free survival (median 7.6 versus 1.8 months [p < 0.01]) and overall survival (median not reached versus 9.9 months [p = 0.04]) compared with PD-L1 expression less than 1%. However, there were no differences in progression-free survival (median 3.9 versus 2.3 months [p = 0.37]) or overall survival (median 9.7 versus 7.6 months [p = 0.60]) between PD-L1 expression of at least 1% and PD-L1expression less than 1% in Min-TCs containing fewer than 100 TCs. CONCLUSION: Single biopsy samples containing at least 100 TCs are required to evaluate PD-L1 expression for predicting patient response to nivolumab.
引用
- Naito T, Udagawa H, Sato J, et al. A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma. J Thorac Oncol. 2019. PMID: 31260834. doi:10.1016/j.jtho.2019.06.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。